像多多一样死去:将危害益处分析和3R原则应用于对动物进行的顺势疗法的动物研究
David Shaw1,2, David Mawufemor Azilagbetor3,4, Edwin Louis-Maerten3
1Institute for Biomedical Ethics, University of Basel, Basel, Switzerland david.shaw@unibas.ch.
Journal of medical ethics
|November 20, 2025
概括
动物研究的伦理准则,包括3R (取代,减少,完善) 和危害益处分析 (HBA),实际上禁止兽医顺势疗法研究. 应用这些原则表明,这种研究在科学上是不合理的,在道德上是不允许的.
科学领域:
- 兽医伦理学 兽医伦理学
- 动物研究法规动物研究法规
- 顺势疗法研究 顺势疗法研究
背景情况:
- 动物研究需要道德上的理由,遵守3Rs (取代,减少,完善) 和危害益处分析 (HBA).
- 在确定研究中使用动物的伦理允许性方面,HBA是至关重要的.
- 目前的法规要求对所有动物研究进行伦理审查和批准.
研究的目的:
- 在伦理上分析兽医顺势疗法研究.
- 将3R原则和HBA应用到对动物进行的顺势疗法研究中.
- 确定在兽医顺势疗法研究中使用动物的科学和道德价值.
主要方法:
- 应用3R原则 (取代,减少,完善) 在兽医顺势疗法研究中.
- 对拟议的动物顺势疗法研究进行危害益处分析 (HBA).
- 对现有或拟议的兽医顺势疗法研究方案的伦理审查.
主要成果:
- 3R和HBA的正确应用表明,对动物进行顺势疗法研究缺乏科学理由.
- 伦理评估显示,动物痛苦的潜在危害超过了顺势疗法研究中任何所谓的好处.
- 非动物替代方法足以研究顺势疗法,使动物使用不必要.
结论:
- 在遵守3Rs和HBA时,涉及动物的兽医顺势疗法研究在伦理上是不合理的.
- 伦理动物研究的原则实际上排除了在顺势疗法研究中使用动物的可能性.
- 科学和伦理标准要求停止基于动物的兽医顺势疗法研究.
相关概念视频
Ethics in Research
25.4K
Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.
25.4K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
387
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
387
Preclinical Development: Overview
5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K


